Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | MRD assessment in CLL

Danielle Brander • 2 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Measurable residual disease is playing a larger role in treatment assessment of chronic lymphocytic leukemia (CLL). This topic is explored by Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Danielle Brander

1:49
The management of Richter's transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023
1:13
Exciting updates in CLL: advancing treatment for patients with double-refractory disease
Danielle Brander • 8 Dec 2023
1:46
Managing the side effects associated with BTKi treatment for CLL
Danielle Brander • 8 Dec 2023
2:06
Unmet need: CLL patients intolerant to novel therapies
Danielle Brander • 22 Sep 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals